Abstract:Monkeypox (MPX), a smallpox-like zoonotic infectious disease caused by the monkeypox virus (MPXV), was first detected in laboratory animals in 1958. Since the eradication of the smallpox virus in the 80s of the 20th century, MPXV has become one of the members of the pox virus family with the greatest public health impact, mainly in the central and western regions of Africa. However, since May 7, 2022, human cases of MPXV infection have been reported in several countries outside endemic areas in Africa. As of July 15, 2022, based on the latest data from the US Centers for Disease Control and Prevention, there have been at least 1,814 suspected or confirmed cases in the US, and a total of 12,556 confirmed cases have been reported in 68 countries around the world. The World Health Organization (WHO) has said that the spread of MPX epidemics in more than 70 countries is an "extraordinary" situation, listing it as a global emergency. This paper mainly reviews the physicochemical characteristics, gene characteristics, pathogenic mechanism, transmission mechanism, and clinical features of MPXV etiology. It also discusses and summarizes the current prevention and treatment options, in order to provide reference for the current exploration of monkeypox prevention and treatment.

Research progress of Monkeypox and its current prevention and treatment options